

Bersama ini saya lampirkan kelengkapan korespondensi dengan Jurnal Internasional, Bali Medical Journal 2023, P-ISSN.2089-1180, E-ISSN: 2302-2914, Volume 12, Number 2: 2040-2045, terlampir.

Demikian dapat disampaikan, atas perhatiannya diucapkan terima kasih.

Rekap Korespondensi dengan Jurnal Internasional, Bali Medical Journal

<b>No</b>	<b>Tanggal</b>	<b>Uraian</b>	<b>Halaman</b>	<b>Ket</b>
1	25 April 2023	Confirmation about manuscript submission (Bali Medical Journal)	Page 1	
2	25 April 2023	Receive revision (Bali Medical Journa)	Page 5	
3	5 Mei 2023	Submit revision to Bali Medical Journal	Page 7	
6	26 Mei 2023	Acceptance confirmation from Bali Medical Journal	Page 8	
7	3 Juni 2023	Receive letter of acceptance	Page 8	
8	24 Juni 2023	Confirmation about the article has been online	Page 9	
9	10 Oktober 2023	Published manuscript confirmation letter	Page 10	



Editor Bali Medical Journal &lt;editorbalimedicaljournal@gmail.com&gt;

**Revision Required [BaliMedJ] [Manuscript ID: 4568]**

11 messages

Editor Bali Medical Journal &lt;editorbalimedicaljournal@gmail.com&gt;

Tue, Apr 25, 2023 at 12:45 PM

To: Achmad Lefi &lt;achmad.lefi@fk.unair.ac.id&gt;

Dear Authors,

Thank you for submitting your article entitled: "**Correlation of serum D-dimer level and the event microvessel cardiac thrombosis observed on core biopsy in post mortem COVID-19 Patients in Dr. Soetomo Hospital Surabaya, Indonesia**"

Based on our author guidelines, Your article fulfilled the minimal required structure,

<https://www.balimedicaljournal.org/index.php/bmj/pages/view/authorguidlines>

In order to have a better-structured article, we suggest you edit based on a checklist and the collection in our archive ([https://www.balimedicaljournal.org/index.php/bmj/issue/archive\\_](https://www.balimedicaljournal.org/index.php/bmj/issue/archive_)).

According to the new International regulation, please fulfill the requirements below:

1. Ethical clearance number/statement and/or informed consent at the end of the manuscript (**Confirmed**).
2. Please state your conflict of interest in the paper. (**Unconfirmed**)
3. Please state the funding (if any) in your paper. (**Unconfirmed**)
4. Please state each author's contribution. (**Unconfirmed**)
5. Please fulfil the author's contribution form (**See attachment below**).
6. Please fulfil the ICMJE author form (**See attachment below**).
7. Please write an abstract in English comprising Introduction, Case presentation, and Conclusion section with no more than 350 words. Please also write 3-6 keywords.
8. Based on our proofreading application, we detected 143 critical grammatical errors.
9. All citation writing should follow the Vancouver superscript style and references writing should also follow Vancouver style.

According to our initial review, your article needs Moderate Revision. Please revise your article and send it back to us in **7 days**

Thank you for trusting us with your hard work and we are looking forward to your response.

Warm regards,

Executive Editor BaliMedJ

--

**Bali Medical Journal (BaliMedJ)****P-ISSN:** 2089-1180**E-ISSN** 2302-2914

Indexed at:

**Web of Science (WOS) Clarivate Analytics****SCOPUS Elsevier****All Indexing Organisation**

---

**2 attachments**



**01. Contribution Details.docx**  
15K



**01. ICMJE.pdf**  
658K

STROBE Statement—Checklist of items that should be included in reports of *cross-sectional studies*

	Item No	Recommendation	Reported on page No
<b>Title and abstract</b>	1	(a) Indicate the study’s design with a commonly used term in the title or the abstract	The study design has already indicated in the abstract
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	The abstract has presented informative and balanced summary of the study
<b>Introduction</b>			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	The background of the study has been clearly explained.
Objectives	3	State specific objectives, including any prespecified hypotheses	The objective(s) of the study clearly stated in the introduction section and abstract section
<b>Methods</b>			
Study design	4	Present key elements of study design early in the paper	Clearly presented in the paper
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	The setting, location, and relevant dates has been described
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants	The inclusion and exclusion criteria has been clearly described.
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	The outcome of the study has been stated in the paper
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	Clearly described in method section
Bias	9	Describe any efforts to address potential sources of bias	Not described
Study size	10	Explain how the study size was arrived at	Not described in the paper
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	Data analysis has been clearly described using descriptive, logistic regression model
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	The statistical method has been described
		(b) Describe any methods used to examine	N/A

		subgroups and interactions	
		(c) Explain how missing data were addressed	Not explained in the paper
		(d) If applicable, describe analytical methods taking account of sampling strategy	N/A
		(e) Describe any sensitivity analyses	N/A
<b>Results</b>			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	N/A
		(b) Give reasons for non-participation at each stage	Not described
		(c) Consider use of a flow diagram	Not described
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	The characteristics has been described in table 1
		(b) Indicate number of participants with missing data for each variable of interest	N/A
Outcome data	15*	Report numbers of outcome events or summary measures	N/A
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	ROC analysis and mean comparison differences
		(b) Report category boundaries when continuous variables were categorized	N/A
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	N/A
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	Only descriptive
<b>Discussion</b>			
Key results	18	Summarise key results with reference to study objectives	Well described
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	The limitation not stated in the discussion section.
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	The interpretation of the results obtained has been carefully interpreted with comparison of results of similar studies
Generalisability	21	Discuss the generalisability (external validity) of	Not clearly described

the study results

---

### Other information

---

Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	Not described
---------	----	---	---------------

---

\*Give information separately for exposed and unexposed groups.

We advice the following revision:

1. Please not use all capital in Running title
2. Make sure to add author name and affiliation with corresponding email after the running title
3. Please divide the abstract into intro, method, result, and conclusion.
4. Introduction section has to describe the urgency to evaluate role d dimer compared to core biopsy as predictive markers for microvascular thrombus in person with covid 19
5. Kindly describe the aim of the study at the introduction section.
6. Kindly cite all table and figure in the text
7. Result doesn't mention any conclusion your findings in result section
8. Discussion must compare your current findings to other simmiliar findings
9. Result section of this study findings, there is no significant difference in d dimer level in microvascular thrombus formation. As we all know covid-19 is mainly causing acute coronary syndrome during hispitalization. Is there specific reasoning for this findings?
10. Make sure to add limitation of the study at the end of discussion section.
11. Please add conclusion that comprehend the whole findings of your result
12. Kindly double check your manuscript all the reference must be cited in the text or vice versa.
13. Make sure to add conflict of interest, funding, acknowledgement, and ethical aspect of the study. Since those kind of thing are very important in journal article.

### Journal:

1. Thomas MC. Diuretics, ACE inhibitors and NSAIDs – the triple whammy. *Med J Aust.* 2000;172:184–185.
2. Guilbert TW, Morgan WJ, Zeiger RS, Mauger DT, Boehmer SJ, Szeffler SJ, et al. Long-term inhaled corticosteroids in preschool children at high risk for asthma. *N Engl J Med.* 2006;354:1985–97.

### WEB citation:

1. Thomas ABC. Vancouver reference style [Internet]. Oaktown (ON): University of Oaktown, Department of Science; 2007 Nov 1 [updated 2008 Jan 11; cited 2008 Feb 19]. Available from: <http://www.org-name.org>

### Book Chapter:

1. Bjork CE Jr, McLeod RD. Formatting citations. In: Laurent B 3rd, Cool JR, editors. *A history of citations and references.* 5th ed. Geneva (Switzerland): Tangelo Press; 2006. p. 93-7.



**Whole Book:**

1. Thomas ABC, editor. Vancouver reference style: a history. New York: Z&E Publishers; 2007. 582 p.

**Achmad Lefi** <achmad.lefi@fk.unair.ac.id>  
To: Editor Bali Medical Journal <editorbalimedicaljournal@gmail.com>

Fri, May 5, 2023 at 8:22 AM

Dear Bali Medical Journal editorial team,

Here we attached the revision manuscript according to revision and first review. We also have fulfilled the ICMJE and contribution details in the file attached below.

Thank you

[Quoted text hidden]

---

**3 attachments**



**01. Contribution Details fulfill.docx**

16K



**01. ICMJE-fulfill.pdf**

905K



**Manuscript Revision\_ Correlation of serum D-dimer level.docx**

12K

---

<https://mail.google.com/mail/u/0/?ik=e6ae7e28dd&view=pt&search=all&permthid=thread-a:r2776966833755275759&simpl=msg-a:r-3505752559...>

2/5



---

**Editor Bali Medical Journal** <editorbalimedicaljournal@gmail.com>  
To: Achmad Lefi <achmad.lefi@fk.unair.ac.id>

Fri, May 26, 2023 at 10:16 AM

Dear authors,

Thank you for your revision, after having a discussion based on our initial review, and adding some comments from our associate editor, we decided to accept your article with some revisions required. To continue the peer review process, please confirm that you have paid the article processing charge. A separate email has been sent with the payment details. Or you can simply click: <https://www.paypal.com/invoice/p/#FQDMLGL23J295UHM>

Unfortunately, we still found 46 critical grammar errors, If you want us to fix this for you, we will charge an extra 150 USD for proofreading and editing (by native English Medical Speaker)

Best regards,

Editorial Board Member  
[Quoted text hidden]

---

 **INVOICE OF PAYMENT PUBLICATION 4568.pdf**  
26K

---

Achmad Lefi <achmad.lefi@fk.unair.ac.id>  
To: Editor Bali Medical Journal <editorbalimedicaljournal@gmail.com>

Wed, May 31, 2023 at 1:04 PM

Dear editorial team,

Thank you for your confirmation.

I agree with the suggestion of the editorial board for the proofreading process. I have transferred the article processing fee and proofreading fee to the account of INTISARI SAINS MEDIS. Here I sent you the attachment of the payment for my article.

Thank you for your consideration.  
[Quoted text hidden]

---

 **PAYMENT PROOF – BALIMEDJ-4568.pdf**  
189K

---

**Editor Bali Medical Journal** <editorbalimedicaljournal@gmail.com>  
To: Achmad Lefi <achmad.lefi@fk.unair.ac.id>

Sat, Jun 3, 2023 at 11:22 AM


Dear authors,

We already confirmed your payment, here we send the letter of acceptance (LoA) of your publication. Thank you for trusting us. We kindly wait for your other publications.

Best regards,

Editorial Board Member  
[Quoted text hidden]

---

 **LOA 4568 - BaliMedJ.pdf**  
26K

---

**Achmad Lefi** <achmad.lefi@fk.unair.ac.id>

Sun, Jun 4, 2023 at 9:02 AM

To: Editor Bali Medical Journal <editorbalimedicaljournal@gmail.com>

Dear editorial team,

We already received the LoA, Thank you very much.

[Quoted text hidden]

---

**Editor Bali Medical Journal** <editorbalimedicaljournal@gmail.com>

Sat, Jun 24, 2023 at 11:22 PM

To: Achmad Lefi <achmad.lefi@fk.unair.ac.id>

Dear Authors,

Your article has been online and you can find it at the link below:

<https://www.balimedicaljournal.org/index.php/bmj/article/view/4568>

Thank you for trusting us with your hard work.

Best regards,

Editorial Board Member

[Quoted text hidden]

<https://mail.google.com/mail/u/0/?ik=e6ae7e28dd&view=pt&search=all&permthid=thread-a:r2776966833755275759&simpl=msg-a:r-3505752559...>

5/5

Number : 4568/BaliMedJ/Denpasar-Bali/2023 Attachment : -  
About : Confirmation Letter

Denpasar, 10 October 2023

To whom it may concern,

I, as the Editor in Chief of **Bali Medical Journal (BaliMedicalJournal.org)**  
(Indexed by Scopus Elsevier and Web of Science, Clarivate Analytics), at this moment declare that:

Published Manuscript in Bali Medical Journal with Title :

**“Correlation of serum D-dimer level and the event microvessel cardiac thrombosis observed on core biopsy in post mortem COVID-19 Patients in Dr. Soetomo Hospital Surabaya, Indonesia”**

**Author :**

Achmad Lefi<sup>1\*</sup>, Lalu Galih Pratama Rinjani<sup>1</sup>, Muhammad Yusuf Alsagaff<sup>1</sup>, Raden Mohammad Budiarto<sup>1</sup>, Priangga Adi Wiratama<sup>2</sup>, Ety Hary Kusumastuti<sup>2</sup>, Isnin Anang Marhana<sup>3</sup>, Alfian Nur Rosyid<sup>3</sup>, Dwi Wahyu<sup>3</sup>, Bambang Pujo Semedi<sup>4</sup>, Ricardo Adrian Nugraha<sup>1</sup>, Ryan Ernast Intan<sup>1</sup>, Muhammad Ramadhan<sup>1</sup>, Ika Caesarina<sup>1</sup>, Asiyah Nurul Fadila<sup>1</sup>, Muhammad Surya Tiyantara<sup>1</sup>, Gilang Muhammad Setyo Nugroho<sup>3</sup>, Ummi Maimunah<sup>5</sup>, Edi Suyanto<sup>6</sup>, Adhitri Anggoro<sup>3</sup>, I Komang Rusgi Yandi<sup>3</sup>, Jilieanastasia Godrace Lilihata<sup>4</sup>

<sup>1</sup>Department of Cardiology and Vascular Medicine, Airlangga University, Dr. Soetomo General Hospital, Surabaya, 60286, Indonesia;

<sup>2</sup>Department of Pathology Anatomy, Airlangga University, Dr. Soetomo General Hospital, Surabaya, 60286, Indonesia;

<sup>3</sup>Department of Pulmonology and Respiratory Medicine, Faculty of Medicine, Universitas Airlangga – Dr. Soetomo General Academic Hospital, Surabaya, 60286, Indonesia;

<sup>4</sup>Department of Anesthesiology and Reanimation, Faculty of Medicine, Universitas Airlangga University – Dr. Soetomo General Academic Hospital, Surabaya, 60286, Indonesia;

<sup>5</sup>Department of Internal Medicine, Faculty of Medicine, Universitas Airlangga – Dr. Soetomo General Academic Hospital, Surabaya, 60286, Indonesia;

<sup>6</sup>Department of Forensics and Medicolegal Medicine, Faculty of Medicine, Universitas Airlangga – Dr. Soetomo General Academic Hospital, Surabaya, 60286, Indonesia.

Published in the Bali Medical Journal Volume 12 Number 1 2023  
(<https://www.balimedicaljournal.org/index.php/bmj/article/view/4194>)

Has gone through the process of Proofreading, editing and Review the manuscript before being published.

**Agreed/Menyetujui by:**

**Bali Medical Journal**



**Prof. Dr. dr. Sri Maliawan, Sp.BS (K)**  
**Editor in Chief**

## Contribution Details

	Contributor
Concepts`	: Galih Pratama Rinjani, Achmad Lefi, Muhammad Yusuf Alsagaff, R. Mohammad Budiarto, Priangga Adi Wiratama, Alfian Nur Rosyid, Ummi Maimunah
Design	: Galih Pratama Rinjani, Achmad Lefi, R. Mohammad Budiarto, Etty Hary Kusumastuti, Alfian Nur Rosyid, Dwi Wahyu, Bambang Pujo Semedi, Ricardo Adrian Nugraha, Muhammad Surya Tiyantara, Edi Suyanto, I Komang Rusgi Yandi
Definition of intellectual content	: Galih Pratama Rinjani, Achmad Lefi, Muhammad Yusuf Alsagaff, R. Mohammad Budiarto, Priangga Adi Wiratama, Alfian Nur Rosyid, Ummi Maimunah
Literature search	: : Galih Pratama Rinjani, Achmad Lefi, R. Mohammad Budiarto, Etty Hary Kusumastuti, Alfian Nur Rosyid, Dwi Wahyu, Bambang Pujo Semedi, Ricardo Adrian Nugraha, Muhammad Surya Tiyantara, Edi Suyanto, I Komang Rusgi Yandi
Clinical studies	: Galih Pratama Rinjani, Priangga Adi Wiratama, , Dwi Wahyu, Muhammad Ramadhan, Asiyah Nurul Fadila, Gilang Muhammad Setyo Nugroho, Adhitri Anggoro, Jilleanastasia Godrace Lilihata
Experimental studies	: Galih Pratama Rinjani, Priangga Adi Wiratama, , Dwi Wahyu, Muhammad Ramadhan, Asiyah Nurul Fadila, Gilang Muhammad Setyo Nugroho, Adhitri Anggoro, Jilleanastasia Godrace Lilihata
Data acquisition	: Galih Pratama Rinjani, Priangga Adi Wiratama, , Dwi Wahyu, Muhammad Ramadhan, Asiyah Nurul Fadila, Gilang Muhammad Setyo Nugroho, Adhitri Anggoro, Jilleanastasia Godrace Lilihata
Data analysis	: Galih Pratama Rinjani, Achmad Lefi, Muhammad Yusuf Alsagaff, Priangga Adi Wiratama, Etty Hary Kusumastuti, Alfian Nur Rosyid, Ricardo Adrian Nugraha, Ryan Ernest Intan, Ika Caesarina
Statistical analysis	: Galih Pratama Rinjani, Achmad Lefi, Ryan Ernest Intan

Manuscript preparation	: Galih Pratama Rinjani, Muhammad Yusuf Alsagaff, Priangga Adi Wiratama, Alfian Nur Rosyid, Ricardo Adrian Nugraha
Manuscript editing	: Galih Pratama Rinjani, R. Mohammad Budiarto, Etty Hary Kusumastuti, Ryan Ernest Intan
Manuscript review	: Achmad Lefi, Muhammad Yusuf Alsagaff, , Dwi Wahyu, Bambang Pujo Semedi, I Komang Rusgi Yandi, Muhammad Surya Tiyantera
Guarantor	: Achmad Lefi

## ICMJE Form for Disclosure of Potential Conflicts of Interest

### Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

#### 1. Identifying information.

#### 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

#### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

#### 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

#### Relationships not covered above.

#### 5. Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

**Other:** Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued

**Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your patent

## ICMJE Form for Disclosure of Potential Conflicts of Interest

### Section 1. Identifying Information

1. Given Name (First Name)  
Achmad

2. Surname (Last Name)  
Lefi

3. Date  
1 May 2023

4. Are you the corresponding author?  Yes  No

5. Manuscript Title

Correlation of serum D-dimer level and the event microvessel cardiac thrombosis observed on core biopsy in post mortem  
— COVID-19 Patients in Dr. Soetomo Hospital Surabaya, Indonesia

6. Manuscript Identifying Number (if you know it)

### Section 2. The Work Under Consideration for Publication

Did you or your institution **at any time** receive payment or services from a third party (government, commercial, private foundation, etc.) for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)?

Are there any relevant conflicts of interest?  Yes  No

### Section 3. Relevant financial activities outside the submitted work.

Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were **present during the 36 months prior to publication**.

Are there any relevant conflicts of interest?  Yes  No

### Section 4. Intellectual Property -- Patents & Copyrights

Do you have any patents, whether planned, pending or issued, broadly relevant to the work?  Yes  No

## ICMJE Form for Disclosure of Potential Conflicts of Interest

---

### Section 5.

#### Relationships not covered above

Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

- Yes, the following relationships/conditions/circumstances are present (explain below):
- No other relationships/conditions/circumstances that present a potential conflict of interest

At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.

### Section 6.

#### Disclosure Statement

Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

I, Achmad Lefi do not have a financial interest / arrangement of affiliation with one or more organization that could be perceived as a real or apparent conflict of interest in the context of the subject of this presentation

### Evaluation and Feedback

Please visit <http://www.icmje.org/cgi-bin/feedback> to provide feedback on your experience with completing this form.



## Letter of Acceptance

21 June 2023

**Dear: Lalu Galih Pratama Rinjani<sup>1</sup>, Achmad Lefi<sup>1\*</sup>, Muhammad Yusuf Alsagaff<sup>1</sup>, R mohammad Budiarto<sup>1</sup>, Priangga Adi Wiratama<sup>2</sup>, Ety Hary Kusumastuti<sup>2</sup>, Isnin Anang Marhana<sup>3</sup>, Alfian Nur Rosyid<sup>3</sup>, Dwi Wahyu<sup>3</sup>, Bambang Pujo Semedi<sup>4</sup>, Ricardo Adrian Nugraha<sup>1</sup>, Ryan Ernast Intan<sup>1</sup>, Muhammad Ramadhan<sup>1</sup>, Ika Caesarina<sup>1</sup>, Asiyah Nurul Fadila<sup>1</sup>, Muhammad Surya Tiyantera<sup>1</sup>, Gilang Muhammad Setyo Nugroho<sup>3</sup>, Ummi Maimunah<sup>5</sup>, Edi Suyanto<sup>6</sup>, Adhitri Anggoro<sup>3</sup>, I Komang Rusgi Yandi<sup>3</sup>, Jilieanastasia Godrace Lilihata<sup>4</sup>**

<sup>1</sup> Department of Cardiology and Vascular Medicine, Universitas Airlangga, Dr. Soetomo General Hospital, Surabaya, 60286, Indonesia

<sup>2</sup>Department of Pathology Anatomy, Universitas Airlangga, Dr. Soetomo General Hospital, Surabaya, 60286, Indonesia

<sup>3</sup>Department of Pulmonology and Respiratory Medicine, Faculty of Medicine, Universitas Airlangga – Dr. Soetomo General Academic Hospital, Surabaya, 60286, Indonesia

<sup>4</sup>Department of Anesthesiology and Reanimation, Faculty of Medicine, Universitas Airlangga University – Dr. Soetomo General Academic Hospital, Surabaya, 60286, Indonesia

<sup>5</sup>Department of Internal Medicine, Faculty of Medicine, Universitas Airlangga – Dr. Soetomo General Academic Hospital, Surabaya, 60286, Indonesia

<sup>6</sup>Department of Forensics and Medicolegal Medicine, Faculty of Medicine, Universitas Airlangga – Dr. Soetomo General Academic Hospital, Surabaya, 60286, Indonesia

\*Corresponding author: [achmad.lefi@fk.unair.ac.id](mailto:achmad.lefi@fk.unair.ac.id)

I am very excited to accept your paper entitled:

**“Correlation of serum D-dimer level and the event microvessel cardiac thrombosis observed on core biopsy in post mortem COVID-19 Patients in Dr. Soetomo Hospital Surabaya, Indonesia.”**

Your paper will be published in the issue of Vol. 12 Number 2, 2023.

<http://dx.doi.org/10.15562/bmj.v12i2.4568>

(Online Link: <http://balimedicaljournal.org/index.php/bmj/article/view/4568>).

And it usually takes 2 to 4 months for your journal to show up at Google Scholar, but if you need it fast, you may add it up manually using your google scholar account. The CrossRef and DOI number usually activate in 3 until 6 months.

Bali Medical Journal is indexed in Web of Sciences, Scopus, and many other indexing organization: <http://balimedicaljournal.org/index.php/bmj/pages/view/indexing>

1. Web of Science (Clarivate Analytics)
2. Scopus (Elsevier)
3. USA National Library of Medicine (Pubmed)
4. NIH National Institutes of Health
5. HINARI Research in Health
6. International Committee of Medical Journal Editors
7. DOAJ Directory of Open Acces Journals
8. SINTA-Science and Technology Index
9. Portal Garuda
10. Google Scholar
11. DOI Crossref
12. EBSCO Open Science Directory
13. Sherpa/Romeo
14. Ulrichsweb.com™ [Proquest]



- 15. InCites Journal Citation Reports (Web of Science)
- 16. Harvard Library
- 17. Index Copernicus
- 18. National Library of Australia
- 19. University of Denmark
- 20. Library of Science and Technology (China)

- 21. ETH Bibliothek (Switzerland)
- 22. SJIF Journal Rank
- 23. Science Impact Factor (SIF)
- 24. Genamics
- 25. ASEAN Citation Index (ACI)
- 26. UDL-Edge (Malaysia)

Please do not hesitate to contact us if you need anything. It has been a pleasure for us to proofread and edit your work, and we are looking forward to your colleagues and your other papers in the near future.

Agreed/Menyetujui by:

**Menyetujui,**  
**Bali Medical Journal**  
  
Prof. Dr. dr. Sri Maliawan, SpBS (K)  
**Editor in Chief**

**Menyetujui,**  
**Bali Medical Journal**  
  
Prof. Dr. Ir. Ida Bagus Putra Manuaba, MPhil  
**Associate Editor**



## Bali Medical Journal Worthy of Publication

Managing Editor:

[isainsmedis@gmail.com](mailto:isainsmedis@gmail.com)

Journal Website:

<https://www.balimedicaljournal.org/index.php/bmj>

Invoice no: **4568-11052023**  
 Invoice date: **June 11<sup>th</sup> 2023**  
 Recent Status: **PAID**  
 Submission due date: **Valid until June 15<sup>th</sup> 2023**

Bill to:

[achmad.lefi@fk.unair.ac.id](mailto:achmad.lefi@fk.unair.ac.id)

Description	Quantity	Price	Amount
Basic Administration and Article Processing Charge	1	USD 1250	USD 1250
Correlation of serum D-dimer level and the event microvessel cardiac thrombosis observed on core biopsy in post mortem COVID-19 Patients in Dr. Soetomo Hospital Surabaya, Indonesia			
Proofread, editing, and reviewing of Manuscript	1	USD 150	USD 150
Journal style and Manuscript Vocabulary and English improvement Citation format	1	USD 150	USD 150
<b>Subtotal</b>			<b>USD 1550</b>
<b>Tax (0,05%)</b>			<b>USD 8</b>
<b>Total</b>			<b>USD 1558</b>

\*Note please kindly adopt USD exchange to IDR day per day at the mean time you pay the respective APC (as per today the exchange rate USD to IDR equal to Rp. 14.977; the total ammount of APC as per today is Rp. 23.334.166).

All of the payment can be transferred to Indonesian Bank Account:  
**Bank Syariah Indonesia/Bank Syariah Mandiri (BSI/BSM): 7099787570**

On behalf of: **INTISARI SAINS MEDIS**

Notes: *Letter of Acceptance (LoA)* of publication include with Volume, Issues, year of publication, and DOI number of manuscript will be processed soon after full of payment.